Header Logo

Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.

Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Ruhlmann CH, Sayegh P, Hesketh PJ. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation. Support Care Cancer. 2023 Dec 22; 32(1):53.

View in: PubMed